Letter | Published:

Effects in vitro of the proposed antisickling agent DBA

Nature volume 272, pages 833834 (27 April 1978) | Download Citation

Subjects

Abstract

A VARIETY of antisickling substances, both synthetic and naturally occurring, have been studied for their potential value as agents for the treatment of sickle cell disease. 3,4-dihydro-2, 2-dimethyl-2H-l-benzopyran-6-butyric acid (DBA), a chemically modified derivative of xanthoxylol isolated from Fagara zanthoxyloides, has been reported to prevent as well as reverse sickling of sickle cell anaemia erythrocytes1. 10 mM DBA was described as being able virtually to abolish sickling within a period of 30 min1. We have examined the effect of DBA on washed erythrocytes prepared from blood of sickle cell anaemia patients, and report here that we have been unable to demonstrate any antisickling effect of DBA.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nature 258, 743 (1975).

  2. 2.

    , , & Lloydia 38, 387 (1975).

  3. 3.

    , , & Proc. natn. Acad. Sci. U.S.A. 71, 4718 (1974).

  4. 4.

    , Blood 33, 884 (1969).

Download references

Author information

Affiliations

  1. Division of Hematology, Children's Memorial Hospital, 2300 Children's Plaza, Chicago, Illinois 60614

    • GEORGE R. HONIG
    • , LOYDA N. VIDA
    •  & CHRISTINE FERENC

Authors

  1. Search for GEORGE R. HONIG in:

  2. Search for LOYDA N. VIDA in:

  3. Search for CHRISTINE FERENC in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/272833a0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.